濮阳东方医院男科割包皮价格便宜(濮阳东方男科医院割包皮手术安全吗) (今日更新中)

The catchy tune kids can’t get enough of, and parents love to hate, “Baby Shark” is officially the most viewed video ever on YouTube at more than 7.1 billion views.The song was recorded by then-10-year-old Korean-American singer Hope Segoine and produced by South Korean educational company under their Pinkfong brand. It was originally uploaded to YouTube on June 17, 2016.In 2019, the song got into the Billboard Top 100 chart.The previous record-holder on YouTube was the 2017 single “Despacito” by Puerto Rican singers Luis Fonsi and Daddy Yankee. That video was uploaded in January 2017 and has about 7.05 billion views.With the repetitive lines and easy dance moves, some parents might be wondering why it took “Baby Shark” so long to get to the top of YouTube’s most-watched list. 795

The Columbus Police Department says it is preparing for demonstrations this weekend after a law enforcement officer shot and killed a man as he entered his own home earlier this month.Casey Goodson, 23, was shot and killed by a Franklin County sheriff's deputy on Dec. 4. Goodson's family says he did not have a criminal record and says it's unclear what crime he could have committed prior to the shooting.Goodson's family and law enforcement authorities have given conflicting reports as to what happened since the day of the shooting. Goodson's grandmother, Sharon Payne, told a 911 dispatcher on the day of the shooting that Goodson had just returned from the dentist when she heard gunfire. She said Goodson then stumbled into the kitchen, bleeding and carrying a Subway sandwich that he had bought on the way home.But according to law enforcement, Franklin County Sheriff's Deputy Jason Meade — who at the time was working for a U.S. Marshal task force that was seeking another suspect — saw Goodson drive by and flash a gun. Police say Meade later confronted Goodson near his car and asked him to drop his weapon. When Goodson refused, Meade fired.Attorneys for Goodson's family say law enforcement's account of the incident omits "key details that raise cause for extreme concern" and allege that police mistook Goodson's sandwich for a gun.Despite law enforcement's claims that Goodson was armed as he drove by officers, they have not said if he was armed at the time the shooting took place. Goodson's family says that he was legally licensed to carry a concealed weapon.There is no video recording of the shooting on file, as Franklin County does not require police to wear body cameras, and its SWAT vehicles are not equipped with dashboard cameras.On Friday, Columbus Police Chief Tom Quinlan said he expects protests to take place throughout the city over the weekend."I hear the cries for this community. I hear your demands for answers, for accountability, for justice ... we understand the issues driving people to gather and speak out," he said. 2071

The Food and Drug Administration says it is re-examining the safety of a medication that was approved despite concerns that not enough was known about the drug's risks.In response to questioning at a budget hearing last week, FDA Commissioner Scott Gottlieb told members of Congress that he would "take another look" at Nuplazid, which is the only drug approved to treat hallucinations and delusions associated with Parkinson's disease psychosis.The medication has been cited as a so-called "suspect" medication in hundreds of deaths voluntarily reported by caregivers, doctors and other medical professionals since it hit the market, as highlighted in a recent CNN report.The FDA told CNN this week that the agency had already begun conducting a new evaluation of the medication when Gottlieb was questioned about it at the hearing. The agency said the review had started several weeks ago."What does it take for a drug like this to be taken off the market?" asked US Rep. Rosa DeLauro, a member and former chair of the congressional subcommittee responsible for funding and overseeing the FDA.DeLauro pressed Gottlieb for answers on his agency's response to the safety concerns surrounding Nuplazid."How many more adverse events do we have to have reported? How many people, quite frankly, have to die? Why does the industry always take precedence over public health and safety?"Tracked by the FDA, the adverse event reports cited by DeLauro do not mean that a suspected medication has been ruled the cause of harm and are typically not the result of official investigations. But the FDA uses the information to monitor potential issues with a drug and can take action as needed: updating a medication's label, for instance, or restricting its use. In rare cases, the agency can even pull a drug off the market.When asked by CNN about what prompted the FDA's new evaluation of Nuplazid, the agency said the decision was based on a number of factors but wouldn't say what those factors were. Instead, it would only comment generally, saying that it identifies "potential signals of serious risk/new safety information" in part by using adverse event data and that the agency is not suggesting physicians stop prescribing the drug or take patients off of it while a safety evaluation is taking place.The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.But physicians, researchers and other medical experts told CNN that the high number of reports deserved a closer look to determine whether they were related to the drug. They also recommended further testing of Nuplazid, worrying that the drug had been approved too quickly, based on too little evidence that it was safe or effective.Nuplazid's review was expedited by the FDA because it had been designated a "breakthrough therapy," meaning it demonstrated "substantial improvement" in patients with serious or life-threatening diseases compared to treatments already on the market.Dr. Paul Andreason, the physician who led the FDA's medical review of Nuplazid, warned that patients taking the drug during the company's clinical trials experienced serious outcomes, including death, at more than double the rate of those taking the placebo. But the FDA ruled that the potential benefits outweighed the risks, agreeing with an advisory committee that cited a lack of safe alternatives and the pleas from family members who claimed the drug was already helping or could help their loved ones.At that advisory committee meeting two years ago, one woman said that her grandmother had been part of the clinical trials for the drug and that Nuplazid had been life-changing."We didn't know what to expect or even if she was on the drug" or a placebo, said Zoey Wade. "We soon realized that she must be taking the drug, because she really returned to herself. Her hallucinations reduced, and she better understood what was real and what was imaginary."Shortly after Nuplazid's release, however, patients' family members, doctors and other health care professionals started reporting "adverse events" possibly linked to the medication -- including deaths, life-threatening incidents, falls, insomnia, nausea and fatigue.During the first 10 months Nuplazid was on the market, 244 deaths were reported to the FDA in which Nuplazid was a "suspect" medication, according to an analysis conducted by the Institute for Safe Medication Practices. FDA data now show that the number of reported deaths has risen to more than 700. In more than 1,000 reports, patients continued to experience hallucinations while on Nuplazid.After CNN published its investigation on Nuplazid, reporters were contacted by family members who said the drug helped tame hallucinations with few apparent side effects and others who said they believe Nuplazid contributed to their family member's decline or death. Some said they had not yet reported these experiences to the drugmaker or the FDA.While the FDA has long been criticized for being too slow to approve drugs, DeLauro seized on its push to streamline the process, lambasting the agency for putting industry interests and efficiency above public health and safety.DeLauro described the number of adverse events and deaths as "staggering" and "unprecedented." She also expressed concern that the drugmaker, Acadia Pharmaceuticals, is attempting to get the drug approved for a larger population: patients who suffer from dementia-related psychosis."I don't know why it should stay on the market, especially when the FDA has not determined it to be safe and while the number of adverse events continues to soar," she told Gottlieb.In response to the congresswoman's remarks, Acadia told CNN that adverse event data alone are "not a comprehensive and accurate indicator of the safety profile of any drug." In response to CNN's earlier report on the drug, Acadia said there are a number of reasons for the higher volume of death reports, including the fact that the company distributes Nuplazid through a network of specialty pharmacies that puts the company in more frequent contact with both patients and caregivers -- meaning Acadia is more likely to receive reports of death, which it is required to pass along to the FDA.Commissioner Gottlieb told the committee that the FDA is careful about the decisions it makes and that there may be a higher tolerance for risk in situations where there is an unmet medical need, "so long as the patient is properly informed of what those risks are." This echoed what he told CNN's Dr. Sanjay Gupta in an interview earlier this month.The FDA previously told CNN that it was aware of Nuplazid's "complex safety profile" at the time of approval and required the drugmaker to place warnings on its labeling. The agency also said that, though it was continuing to monitor available information about Nuplazid, it had "not identified a specific safety issue" not already reflected on the medication's label.DeLauro's office told CNN that it plans to follow up with the FDA about its inquiry into Nuplazid. 7224

The coronavirus pandemic has already caused depleted toilet paper shelves and concerns about meat shortages, but now it’s also to blame for some other, maybe more surprising shortages across the country.Coca-Cola announced at the beginning of July that it was stopping production on Odwalla Juice at the end of the month. On a call with investors, James Quincey, Chairman & Chief Executive Officer of The Coca-Cola Co. said of Odwalla, “In the case of a brand like Odwalla and its chilled direct store delivery, which has struggled over the last several years, we started to stop operations effective July 31. This gives us the flexibility to support our investments in brands like Minute Maid and Simply.”And if you thought you were imagining fewer types of Coke products on store shelves, there’s a good chance you weren’t. A representative from the soft drink giant said in an email, “We continue to see high demand for products consumed at home. We are implementing contingency plans as best we can to get the products people want to store shelves. We appreciate everyone’s patience as we work through these unprecedented times,” going on to say, “we are focusing on the availability of our most popular brands.”“Coke is facing is a different sort of thing right now; it's something that's a shift in demand, which is temporary, and they're not in position to respond to it other than to…put all of their eggs into the baskets that are going out the door fastest,” said William Dickens, University Distinguished Professor and chair of the economics department at Northeastern University.Another issue for Coke likely ties into another shortage – aluminum cans.According to Robert Budway, the president of the Can Manufacturers Institute, the aluminium can industry was seeing demand increase even before the pandemic began because cans are more environmentally friendly than plastic bottles, and the demand has only gone up.“Can manufacturers are fully focused on filling the extraordinary demand from all sectors of the industry’s customer base,” said Budway in a statement. He also said that although there is enough aluminum, can makers have announced the construction of several new plants in the United States and Canada, but they will take between 12 and 18 months to build.Chains like Taco Bell announced they’re trimming the menu too, removing things like the 7-Layer Burrito and Nachos Supreme. And Red Robin Gourmet Burgers ditched a third of its menu.The national burger chain cut 55 items, and a representative pointed to what they told their investors about the changes saying the cuts have resulted in “faster cook times, higher quality food” and say it’s reduced waste.“Sure,” said Dickens. “But why wouldn't they have done it before this, if it made such a big difference? The best explanation is that now they're in a different circumstance, and they just can't afford to produce the type of variety that they did before because they aren't having as many people coming in.”Dickens said everything, each menu item and each flavor of soda, has a specific cost to make. For a business to be profitable, it has to sell a certain number of each offering.So it makes sense that less popular items might hit the road right now.“As for menus and shortages…I think we may very well see more firms follow suit. I know my favorite restaurant is only offering a couple of items compared to what it used to. So I know it's a phenomenon that's out there,” said Dickens. “It's more profitable for [restaurants] to focus on a couple of items that they know that they're going to sell a lot of.”He went on to say what we can expect to see in the next month or year largely depends on how things go with COVID-19 and the subsequent handling of the economy.“I guess my biggest fear is that we're mishandling the economy,” said Dickens.He said that the United States’ economy hasn’t shrunk as much as it might have since the pandemic hit because Congress authorized an extra 0 per week for unemployment benefits. He said that the people who are getting those benefits are also then spending that money on things like food and drink.With the final unemployment supplements already distributed, Dickens predicts people will have less money to spend, which in turn will mean less money in the economy overall, more job layoffs – and a deeper recession. He said that could ultimately mean more shortages – and more businesses closing for good.“We should not let the smart things that were done fade away too early, and this is clearly too early since a large part of the country is still seeing growing numbers of cases,” said Dickens. “They're probably going to have to take action to pull back from re-opening and people are gonna need economic support.” 4769

The Department of Justice announced Wednesday the indictment of two fighters affiliated to the Islamic State group who are alleged to have killed American journalists and aid workers.El Shafee Elsheikh and Alexanda Kotey were previously in U.S. military custody in Iraq and have been transported to Virginia to face trial.Elsheikh and Kotey, both of the United Kingdom, are two of the four ISIS fighters nicknamed "The Beatles" by intelligence officers because of their British accents. They've been linked to the killings of aid workers Peter Kassig and Kayla Mueller and journalists Steven Sotloff and James Foley.“These charges are the product of many years of hard work in pursuit of justice for our citizens slain by ISIS. Although we cannot bring them back, we can and will seek justice on behalf of their memories,” Attorney General William Barr said in a statement. “My message to other terrorists around the world is this — if you harm Americans, you will face American arms on the battlefield, and if you survive that ordeal, you will face American law in our courtrooms with the prospect of many years in an American prison. Either way, you will never live in peace — you will be pursued to the ends of the earth until justice is done.”Barr was not present at Wednesday's press conference as he is currently self-isolating amid a COVID-19 outbreak in the Trump administration. 1395

来源：资阳报